Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Agennix expands phase III talactoferrin registration trial globally

Jan. 25, 2010

Cetuximab as first-line therapy for Menetrier's disease / News in Context

Jan. 25, 2010

ACT Biotech confirms FDA acceptance of ACTB-1003 IND

Jan. 25, 2010

Sunesis completes enrollment of phase Ib/II voreloxin trial

Jan. 25, 2010

Bayer Schering Pharma discovers novel c-Met inhibitors for cancer therapy

Jan. 25, 2010

Cytomics claims novel antiproliferative agents for multidrug resistance cancer

Jan. 25, 2010

4SC commences dosing in a first-in-man phase I study of 4SC-203

Jan. 22, 2010

Sorafenib shows low activity in phase II trial in advanced biliary tract carcinoma

Jan. 22, 2010

Synta Pharmaceuticals discloses Hsp90 inhibitors for the treatment of cancer

Jan. 22, 2010

Everolimus effective in patients with metastatic pancreatic neuroendocrine tumors

Jan. 22, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...